Please login to the form below

Not currently logged in
Email:
Password:

EUSA founder joins Oxford BioTherapeutics as chairman

Bryan Morton has rich experience in oncology

Oxford Biotherapeutics Bryan MortonOncology-focused biotech Oxford BioTherapeutics has appointed industry veteran Bryan Morton as non-executive chairman.

Morton has 30 years' experience in the life sciences industry, including founding and serving as CEO of oncology specialist EUSA Pharma. This company was later sold to Jazz Pharma in 2012 for $700m.

Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.

In addition to his entrepreneurial activities, Morton served as president of Convatec EMEA and spent more than 20 years in various roles at Merck & Co.

“His success in building valuable businesses and knowledge of the cancer space in particular will be important as we look to further develop our pipeline of antibody based cancer medicines to fulfil unmet patient needs,” said Christian Rohlff, CEO and founder of Oxford BioTherapeutics.

28th June 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...

Infographics